The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin in advanced HCC: Updates on the EACH study.
Sumitra Thongprasert
Disclosure not yet available
Shukui Qin
Disclosure not yet available
Ho Yeong Lim
Disclosure not yet available
Vajarabhongsa Bhudhisawasdi
Disclosure not yet available
Xiaoyu Yin
Disclosure not yet available
Wu Gang
Disclosure not yet available
Bong-Seog Kim
Disclosure not yet available
Zhixiang Jian
Disclosure not yet available
Tsai-Shen Yang
Disclosure not yet available
Kunming Rau
Disclosure not yet available